Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Syntara Limited ( (AU:SNT) ) has shared an update.
Syntara Limited announced positive results from its Phase 2a trial of amsulostat in myelofibrosis, showing significant symptom improvement and spleen volume reduction in patients, with no serious adverse events. The company is advancing its clinical pipeline with new trials and strategic appointments, positioning itself strongly in the blood-cancer and dermatology markets.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is a clinical-stage drug development company focused on creating innovative therapies for various medical conditions. The company is involved in the development of treatments for myelofibrosis, myelodysplastic neoplasms, and dermatological conditions such as hypertrophic and keloid scars.
Average Trading Volume: 5,061,432
Technical Sentiment Signal: Sell
Current Market Cap: A$50.6M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.